+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Medications Market by Drug Class (Colchicine, Nonsteroidal Anti-Inflammatory Drugs, Recombinant Uricase), Route of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030- Product Image
Gout Medications Market by Drug Class (Colchicine, Nonsteroidal Anti-Inflammatory Drugs, Recombinant Uricase), Route of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030- Product Image
New

Gout Medications Market by Drug Class (Colchicine, Nonsteroidal Anti-Inflammatory Drugs, Recombinant Uricase), Route of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6128609
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Gout, a metabolic disorder characterized by excruciating joint inflammation and uric acid crystallization, continues to present a significant clinical and economic challenge. Patients experience episodic flares that undermine quality of life and demand targeted pharmacological interventions. Evolving demographics, changing lifestyle factors, and heightened awareness of comorbid risks have collectively underscored the urgency for more effective prevention and management strategies.

This executive summary offers a concise yet thorough overview of the critical drivers shaping the therapeutic landscape for gout medications. It outlines the most transformative innovations, examines the implications of new policy measures on supply chains, and unpacks rich segmentation and regional insights. Additionally, it highlights the leading companies shaping this field, presents strategic recommendations for industry leaders, and describes the rigorous research methodology employed. The aim is to equip decision-makers with an authoritative snapshot of current dynamics and emerging opportunities.

Examining the Confluence of Technological Breakthroughs, Personalized Medicine Advances, and Regulatory Milestones Driving Transformation in Gout Therapeutics

Over the past few years, the gout medications space has been revolutionized by groundbreaking scientific progress and a shift toward individualized patient care. Novel biologic approaches targeting urate crystallization have ushered in therapies that address refractory cases previously considered untreatable. Concurrently, advancements in precision diagnostics and genetic profiling are enabling clinicians to tailor treatment regimens to patient-specific risk factors, optimizing both response rates and tolerability.

Regulatory pathways have similarly adapted, offering accelerated approval mechanisms for high-need therapies and fostering collaborations between academia and industry. Health authorities are increasingly emphasizing real-world evidence and post-marketing surveillance to ensure safety while expediting patient access. Through these converging forces-technological breakthroughs, personalized medicine frameworks, and regulatory innovations-the gout therapeutic landscape is undergoing a profound transformation.

Assessing the Far-Reaching Consequences of 2025 United States Tariff Adjustments on Supply Chains, Pricing Structures, and Access to Gout Medications

Starting in 2025, significant tariff adjustments in the United States have altered the economics of importing active pharmaceutical ingredients and finished therapies used in gout management. Suppliers and manufacturers are experiencing increased costs, prompting a reassessment of global sourcing strategies. For some biologics, which rely on complex supply chains, these tariff shifts have led to negotiations for localized production or partnerships with domestic fill-and-finish facilities to mitigate cost pressure.

These changes have accelerated commercial planning cycles as stakeholders seek to preserve patient access without compromising profitability. Innovative contract structures, including value-based agreements and risk-sharing models, have emerged to offset pricing volatility. In parallel, firms are exploring alternative raw material providers and optimizing inventory management to maintain continuity of supply. As a result, the tariff landscape has become an inflection point compelling manufacturers and payers alike to pursue more resilient, cost-efficient pathways.

Revealing Actionable Insights from Comprehensive Segmentation of Drug Classes, Administration Routes, Distribution Channels, Dosage Forms, and End User Settings

A nuanced view of the gout medications sector reveals opportunity pockets when viewed through multiple segmentation lenses. By classifying therapies according to drug class such as colchicine, nonsteroidal anti-inflammatory drugs with subcategories including ibuprofen, indomethacin, and naproxen, recombinant uricase formulations like pegloticase and rasburicase, uricosuric agents comprising benzbromarone, lesinurad, and probenecid, as well as xanthine oxidase inhibitors such as allopurinol, febuxostat, and topiroxostat, it becomes evident which pipelines and legacy products command the greatest clinical attention.

When considering routes of administration-from intravenous and subcutaneous biologic infusions to oral small molecule tablets and solutions-distinct adoption patterns emerge, driven by patient convenience and healthcare setting capabilities. Equally important, distribution channels spanning hospital-based pharmacies, retail outlets, and online platforms are each evolving in response to shifting purchasing behaviors. Dosage forms ranging from capsules and tablets to injectable and oral solutions underscore the diversity of delivery vehicles, while end user settings including ambulatory surgical centers, clinics, home care environments, and hospitals highlight the critical role of care setting in therapeutic choice and reimbursement pathways.

Illuminating Key Regional Variations in Gout Medication Adoption, Access Dynamics, and Infrastructure across the Americas, EMEA, and Asia-Pacific Markets

Regional dynamics play a pivotal role in shaping the access, adoption, and innovation cycles for gout therapies. In the Americas, robust payer networks and advanced clinical trial infrastructures have accelerated the uptake of novel biologic and small molecule treatments. Collaborative frameworks between government agencies and private stakeholders have fostered price negotiation mechanisms that balance cost containment with patient access ambitions.

Across Europe, the Middle East & Africa, market access strategies vary widely. In several Western European nations, centralized health technology assessments emphasize cost-effectiveness, prompting manufacturers to substantiate real-world value through extensive post-launch data collection. Meanwhile, emerging markets within this region are characterized by infrastructure development and evolving regulatory oversight, shaping a landscape where affordability and scalable distribution solutions are paramount.

In Asia-Pacific, high patient volumes and diverse regulatory environments present both challenges and opportunities. Rapidly expanding biopharmaceutical capabilities in several key markets have led to localized biologic manufacturing, while oral therapies continue to dominate in regions with less developed cold-chain logistics. Government initiatives aimed at improving chronic disease management and expanding universal healthcare coverage are further driving demand for optimized gout treatment options.

Highlighting Major Industry Players Shaping the Gout Therapeutics Space through Strategic Partnerships, Product Innovations, and Market-Led Collaborations

Leading pharmaceutical and biotechnology firms are at the forefront of developing next-generation gout therapies. Established companies have fortified their portfolios through strategic acquisitions of niche pipeline assets, augmenting traditional urate-lowering agents with advanced biologics in development. Biotech innovators are collaborating with academic institutions to explore novel targets beyond uricase inhibition, focusing on molecular pathways that regulate inflammatory cascades and crystal dissolution.

Strategic alliances between small biotech ventures and contract development organizations have accelerated the translation of preclinical candidates into clinical trials. Innovative funding models, including milestone-based partnerships and co-development agreements, have enabled smaller players to bring differentiated assets to proof-of-concept stages. Meanwhile, global pharmaceutical powerhouses leverage extensive commercial networks to secure broad market coverage for both legacy and newly approved therapies, reinforcing their leadership positions in a competitive landscape.

Guiding Industry Leaders with Focused Strategies to Harness Competitive Advances, Novel Therapeutic Pathways, and Evolving Regulatory Frameworks in Gout Care

To maintain market leadership amidst rapid innovation and evolving access considerations, industry stakeholders should prioritize flexible pricing and contracting approaches. Adopting value-based arrangements that link reimbursement to real-world clinical outcomes will enable manufacturers to demonstrate differentiated value while addressing payer constraints. Simultaneously, investment in patient support programs and digital adherence platforms can enhance long-term engagement and reduce disease flares.

Diversifying supply chains through regional manufacturing partnerships will be critical in mitigating tariff-related cost pressures and ensuring supply continuity. Organizations should also strengthen cross-functional collaboration between clinical development, regulatory affairs, and commercial teams to align evidence generation with payers’ data requirements. Ultimately, companies that balance scientific innovation with agile access strategies will be best positioned to capture emerging opportunities and accelerate patient benefit in gout care.

Detailing a Robust Methodological Approach Integrating Expert Interviews, Secondary Data Synthesis, and Analytical Triangulation for Gout Medication Analysis

Our research methodology combined primary engagements with a diverse range of stakeholders and an extensive secondary data synthesis process. Interviews were conducted with key opinion leaders, including rheumatologists, pharmacologists, and healthcare payers, to gather firsthand perspectives on clinical unmet needs, adoption drivers, and commercial imperatives. In parallel, conversations with supply chain experts and policy advisors illuminated the practical implications of tariff adjustments and regulatory shifts.

Secondary research encompassed a systematic review of peer-reviewed publications, regulatory filings, patent registries, and public policy documents. Data points from industry conferences and real-world evidence repositories were triangulated to validate findings and ensure comprehensive coverage. Through iterative validation cycles and cross-referencing primary insights with documented sources, the analysis delivers a robust, multi-dimensional view of the gout medications landscape.

Drawing Informed Conclusions by Synthesizing Market Dynamics, Industry Developments, and Strategic Imperatives to Guide Future Directions in Gout Therapeutics

This synthesis underscores the convergence of scientific breakthroughs, regulatory evolution, and strategic commercial responses that collectively define the current gout treatment environment. Therapeutic innovation has expanded to include advanced biologics and targeted small molecules, while evolving regulatory frameworks are facilitating accelerated access under real-world evidence paradigms. Simultaneously, tariff changes and supply chain complexities underscore the need for resilient manufacturing and pricing strategies.

By weaving together segmentation insights, regional analyses, and corporate strategies, the report illuminates pathways for stakeholder alignment, investment prioritization, and patient-centric care models. The holistic perspective offered herein is designed to guide executives, investors, and clinical leaders in identifying high-impact opportunities and navigating the complexities of a market in transition.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Colchicine
    • Nonsteroidal Anti-Inflammatory Drugs
      • Ibuprofen
      • Indomethacin
      • Naproxen
    • Recombinant Uricase
      • Pegloticase
      • Rasburicase
    • Uricosuric Agents
      • Benzbromarone
      • Lesinurad
      • Probenecid
    • Xanthine Oxidase Inhibitors
      • Allopurinol
      • Febuxostat
      • Topiroxostat
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Dosage Form
    • Capsules
    • Injectable Solutions
    • Oral Solutions
    • Tablets
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Home Care
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Horizon Therapeutics plc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Pfizer Inc.
  • Novartis AG
  • Viatris Inc.
  • Lupin Limited
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Torrent Pharmaceuticals Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of biomarker-driven patient stratification in gout therapy development
5.2. Rising adoption of oral uricase formulations with improved safety profiles
5.3. Expansion of telemedicine-based remote monitoring for chronic gout management
5.4. Development of next-generation xanthine oxidase inhibitors targeting dual pathways
5.5. Emergence of personalized nutrition algorithms to support uric acid reduction
5.6. Growing investment in gene therapy approaches for refractory gout cases
5.7. Impact of real-world evidence studies on optimizing allopurinol dosing strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gout Medications Market, by Drug Class
8.1. Introduction
8.2. Colchicine
8.3. Nonsteroidal Anti-Inflammatory Drugs
8.3.1. Ibuprofen
8.3.2. Indomethacin
8.3.3. Naproxen
8.4. Recombinant Uricase
8.4.1. Pegloticase
8.4.2. Rasburicase
8.5. Uricosuric Agents
8.5.1. Benzbromarone
8.5.2. Lesinurad
8.5.3. Probenecid
8.6. Xanthine Oxidase Inhibitors
8.6.1. Allopurinol
8.6.2. Febuxostat
8.6.3. Topiroxostat
9. Gout Medications Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Gout Medications Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Gout Medications Market, by Dosage Form
11.1. Introduction
11.2. Capsules
11.3. Injectable Solutions
11.4. Oral Solutions
11.5. Tablets
12. Gout Medications Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Clinics
12.4. Home Care
12.5. Hospitals
13. Americas Gout Medications Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gout Medications Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gout Medications Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Horizon Therapeutics plc
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Teva Pharmaceutical Industries Limited
16.3.4. Pfizer Inc.
16.3.5. Novartis AG
16.3.6. Viatris Inc.
16.3.7. Lupin Limited
16.3.8. Cipla Limited
16.3.9. Hikma Pharmaceuticals PLC
16.3.10. Torrent Pharmaceuticals Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GOUT MEDICATIONS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GOUT MEDICATIONS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GOUT MEDICATIONS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GOUT MEDICATIONS MARKET: RESEARCHAI
FIGURE 26. GOUT MEDICATIONS MARKET: RESEARCHSTATISTICS
FIGURE 27. GOUT MEDICATIONS MARKET: RESEARCHCONTACTS
FIGURE 28. GOUT MEDICATIONS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GOUT MEDICATIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. CANADA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. CANADA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 130. CANADA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 131. CANADA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 132. CANADA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 133. CANADA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 134. CANADA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 135. CANADA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. CANADA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. CANADA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. CANADA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. CANADA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. CANADA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. CANADA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. MEXICO GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. MEXICO GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 150. MEXICO GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 151. MEXICO GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. MEXICO GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. MEXICO GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. MEXICO GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. GERMANY GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 238. GERMANY GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 239. GERMANY GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 242. GERMANY GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 243. GERMANY GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. GERMANY GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. GERMANY GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. GERMANY GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 252. GERMANY GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 253. GERMANY GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. GERMANY GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. FRANCE GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. FRANCE GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. FRANCE GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 260. FRANCE GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 261. FRANCE GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. FRANCE GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FRANCE GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. FRANCE GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 270. FRANCE GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 271. FRANCE GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. FRANCE GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. ITALY GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 292. ITALY GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 293. ITALY GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 294. ITALY GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 295. ITALY GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 296. ITALY GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 297. ITALY GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 298. ITALY GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 299. ITALY GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. ITALY GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. ITALY GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. ITALY GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. ITALY GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. ITALY GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. ITALY GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 306. ITALY GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 307. ITALY GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. ITALY GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. SPAIN GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 310. SPAIN GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 311. SPAIN GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 312. SPAIN GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 313. SPAIN GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 314. SPAIN GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 315. SPAIN GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. SPAIN GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. SPAIN GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. SPAIN GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. SPAIN GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. SPAIN GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. SPAIN GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 324. SPAIN GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 325. SPAIN GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. SPAIN GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gout Medications market report include:
  • Horizon Therapeutics plc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Pfizer Inc.
  • Novartis AG
  • Viatris Inc.
  • Lupin Limited
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Torrent Pharmaceuticals Limited

Related Topics

Related Reports

Gout Therapeutics Market by Route Of Administration (Injectable, Oral), Therapy Line (First Line, Second Line, Third Line), Drug Class, Distribution Channel - Global Forecast 2025-2030 - Product Image

Gout Therapeutics Market by Route Of Administration (Injectable, Oral), Therapy Line (First Line, Second Line, Third Line), Drug Class, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action, Product Type, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030 - Product Image

Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action, Product Type, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Gout Disease Treatment - Global Strategic Business Report - Product Image

Gout Disease Treatment - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Gout Therapeutics Market Report 2025 - Product Image

Gout Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gout - Pipeline Insight, 2025 - Product Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.